With a positive prognostic value of the CD5+ DC signature observed for melanoma, lung squamous cell carcinoma, sarcoma, breast cancer, cervical squamous cell carcinoma and endocervical adenocarcinoma patient cohorts, CD5 could be of ubiquitous importance in a broad spectrum of tumors. This evidence concerns the gene CD5 and melanoma.